Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:2062-2071
Published online before print October 15, 2007, doi: 10.1161/CIRCULATIONAHA.107.709360
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
116/18/2062    most recent
CIRCULATIONAHA.107.709360v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grabie, N.
Right arrow Articles by Lichtman, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grabie, N.
Right arrow Articles by Lichtman, A. H.
Related Collections
Right arrow Animal models of human disease
Right arrow Physiological and pathological control of gene expression
Right arrow Myocardial cardiomyopathy disease
Right arrow Other Vascular biology

(Circulation. 2007;116:2062-2071.)
© 2007 American Heart Association, Inc.


Molecular Cardiology

Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8+ T-Cell–Mediated Injury in the Heart

Nir Grabie, PhD; Israel Gotsman, MD; Rosa DaCosta, BA; Hong Pang, MD; George Stavrakis, MSc; Manish J. Butte, MD, PhD; Mary E. Keir, PhD; Gordon J. Freeman, MD, PhD; Arlene H. Sharpe, MD, PhD; Andrew H. Lichtman, MD, PhD

From the Vascular Research Division, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School (N.G., I.G., R.D., H.P., G.S., A.H.L.); Department of Pathology, Harvard Medical School (M.J.B, M.E.K., A.H.S.); and Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School (G.J.F.) Boston, Mass.

Correspondence to Andrew H. Lichtman, MD, PhD, Department of Pathology, Brigham and Women’s Hospital, 77 Ave Louis Pasteur, NRB 752N, Boston, MA 02115. E-mail alichtman{at}rics.bwh.harvard.edu

Received April 13, 2007; accepted August 27, 2007.

Background— PD-L1 and PD-L2 are ligands for the inhibitory receptor programmed death-1 (PD-1), which is an important regulator of immune responses. PD-L1 is induced on cardiac endothelial cells under inflammatory conditions, but little is known about its role in regulating immune injury in the heart.

Methods and Results— Cytotoxic T-lymphocyte–mediated myocarditis was induced in mice, and the influence of PD-L1 signaling was studied with PD-L1/L2–deficient mice and blocking antibodies. During cytotoxic T-lymphocyte–induced myocarditis, the upregulation of PD-L1 on cardiac endothelia was dependent on T-cell–derived interferon-{gamma}, and blocking of interferon-{gamma} signaling worsened disease. Genetic deletion of both PD-1 ligands [PD-L1/2(–/–)], as well as treatment with PD-L1 blocking antibody, transformed transient myocarditis to lethal disease, in association with widespread polymorphonuclear leukocyte–rich microabscesses but without change in cytotoxic T-lymphocyte recruitment. PD-L1/2(–/–) mice reconstituted with bone marrow from wild-type mice remained susceptible to severe disease, which demonstrates that PD-L1 on non–bone marrow–derived cells confers the protective effect. Finally, depletion of polymorphonuclear leukocytes reversed the enhanced susceptibility to lethal myocarditis attributable to PD-L1 deficiency.

Conclusions— Myocardial PD-L1, mainly localized on endothelium, is critical for control of immune-mediated cardiac injury and polymorphonuclear leukocyte inflammation.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
E. D. Reynoso and S. J. Turley
Unconventional antigen-presenting cells in the induction of peripheral CD8+ T cell tolerance
J. Leukoc. Biol., October 1, 2009; 86(4): 795 - 801.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. Kroner, N. Schwab, C. W. Ip, S. Ortler, K. Gobel, K.-A. Nave, M. Maurer, R. Martini, and H. Wiendl
Accelerated Course of Experimental Autoimmune Encephalomyelitis in PD-1-Deficient Central Nervous System Myelin Mutants
Am. J. Pathol., June 1, 2009; 174(6): 2290 - 2299.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. D. Reynoso, K. G. Elpek, L. Francisco, R. Bronson, A. Bellemare-Pelletier, A. H. Sharpe, G. J. Freeman, and S. J. Turley
Intestinal Tolerance Is Converted to Autoimmune Enteritis upon PD-1 Ligand Blockade
J. Immunol., February 15, 2009; 182(4): 2102 - 2112.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
I. Gotsman, A. H. Sharpe, and A. H. Lichtman
T-Cell Costimulation and Coinhibition in Atherosclerosis
Circ. Res., November 21, 2008; 103(11): 1220 - 1231.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Calbo, H. Delagreverie, C. Arnoult, F.-J. Authier, F. Tron, and O. Boyer
Functional Tolerance of CD8+ T Cells Induced by Muscle-Specific Antigen Expression
J. Immunol., July 1, 2008; 181(1): 408 - 417.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Yang, J. Popoola, S. Khandwala, N. Vadivel, V. Vanguri, X. Yuan, S. Dada, I. Guleria, C. Tian, M. J. Ansari, et al.
Critical Role of Donor Tissue Expression of Programmed Death Ligand-1 in Regulating Cardiac Allograft Rejection and Vasculopathy
Circulation, February 5, 2008; 117(5): 660 - 669.
[Abstract] [Full Text] [PDF]